Literature DB >> 21865978

Evaluation of guidelines for management of familial adenomatous polyposis in a multicenter pediatric cohort.

Anne Munck1, Lamia Gargouri, Corinne Alberti, Jerome Viala, Michel Peuchmaur, Catherine Lenaerts, Laurent Michaud, Thierry Lamireau, Jean Francois Mougenot, Alain Dabadie, Chantal Maurage, Alain Lachaux, Michele Scaillon, Jane Languepin, Claire Spyckerelle, Martine Meyer, Sylvianne Olschwang.   

Abstract

OBJECTIVE: To retrospectively assess, in a pediatric multicenter cohort, guidelines for the management of familial adenomatous polyposis (FAP).
METHODS: Ten centers from the French-speaking Pediatric Gastroenterology Hepatology and Nutrition Group provided follow-up data on patients up to 18 years of age. Clinical records, genetic test results, endoscopy with histopathology examination, and therapeutic modalities were reviewed.
RESULTS: A total of 70 children from 47 families were included. When initial consultation resulted from a surveillance program because of an affected family member, 12 of 59 children were already symptomatic. Among 11 patients whose initial consultation was based only on symptoms, families were unaware at the time of a familial FAP history for 7 children, whereas only 4 cases were sporadic. A panel of 27 different pathogenic adenomatous polyposis coli (APC) germ-line mutations and large genomic deletions were identified in 43 families. Extracolonic manifestations were found in half of the patients. As part of the standard practice for initial screening, the entire cohort underwent colonoscopy, which revealed adenoma above an intact rectosigmoid in 8 cases. Prophylactic colectomy was performed in 42 cases; high-grade dysplastic adenoma and 1 invasive carcinoma were detected in 6 children. For timing of surgery, indications were in accordance with recent international guidelines.
CONCLUSIONS: Defining optimal screening and therapeutic modalities in pediatric FAP cohorts is a challenge. Specific advice for genetic screening, endoscopy surveillance, and type of surgery based on recent guidelines is recommended.

Entities:  

Mesh:

Year:  2011        PMID: 21865978     DOI: 10.1097/MPG.0b013e3182198f4d

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.

Authors:  Seth Septer; Caitlin E Lawson; Shrikant Anant; Thomas Attard
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

2.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.

Authors:  Elena M Stoffel; Pamela B Mangu; Stephen B Gruber; Stanley R Hamilton; Matthew F Kalady; Michelle Wan Yee Lau; Karen H Lu; Nancy Roach; Paul J Limburg
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

3.  Presence of c.3956delC mutation in familial adenomatous polyposis patients from Brazil.

Authors:  Caroline Aquino Moreira-Nunes; Diego di Felipe Ávila Alcântara; Sérgio Figueiredo Lima-Júnior; Sandro Roberto de Araújo Cavalléro; Juan Antonio Rey; Giovanny Rebouças Pinto; Paulo Pimentel de Assumpção; Rommel Rodriguez Burbano
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

Review 4.  Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines.

Authors:  Marcia Cruz-Correa; Julyann Pérez-Mayoral; Julie Dutil; Miguel Echenique; Rafael Mosquera; Keila Rivera-Román; Sharee Umpierre; Segundo Rodriguez-Quilichini; Maria Gonzalez-Pons; Myrta I Olivera; Sherly Pardo
Journal:  Hered Cancer Clin Pract       Date:  2017-01-21       Impact factor: 2.857

5.  [Current indications of ileocolonoscopy in children in 2012].

Authors:  A Dabadie; M Bellaiche; J Cardey; A Lachaux; L Michaud; A Morali
Journal:  Arch Pediatr       Date:  2012-09-18       Impact factor: 1.180

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.